Marktanalyse - OTC Pharmaceuticals - North America (NAFTA) Industry Guide

OTC Pharmaceuticals - North America (NAFTA) Industry Guide is an essential resource for top-level data and analysis covering the OTC Pharmaceuticals industry in each of the North American Free Trade Agreement (United States, Canada, and Mexico) countries. The report includes easily comparable data on market value, volume, segmentation and market share, plus full five year market forecasts. It examines future problems, innovations and potential growth areas within the market.

Scope of the Report

* Contains an executive summary and data on value, volume and segmentation

* Provides textual analysis of the industry's prospects, competitive landscape and profiles of the leading companies

* Incorporates in-depth five forces competitive environment analysis and scorecards

* Compares data from the US, Canada and Mexico, alongside individual chapters on each country. .

* Includes a five-year forecast of the industry

Highlights

The OTC pharmaceuticals industry within the NAFTA countries had a total market value of $33,106.2 million in 2010.

Canada was the fastest growing country, with a CAGR of 3.4% over the 2006—10 period.

Within the OTC pharmaceuticals industry, the US is the leading country among the NAFTA bloc, with market revenues of $28,309.4 million in 2010.

The US is expected to lead the OTC Pharmaceuticals industry in the NAFTA bloc, with a value of $32,613.4 million in 2015.

Why you should buy this report

* Spot future trends and developments

* Inform your business decisions

* Add weight to presentations and marketing materials

* Save time carrying out entry-level research

Market Definition

The OTC pharmaceuticals market consists of the retail sale of traditional medicines, cough and cold preparations (tablets, mixtures, lozenges, topical remedies, inhalers), vitamins and minerals (multi-vitamins, single minerals, single vitamins, tonics, cod liver oil), indigestion preparations (tablets, powders, mixtures), analgesics (Paracetamol, Ibuprofen, Aspirinand other analgesics), and medicated skin products (anti-bacteria’s, acne treatments, anti-fungal, disinfectants and other), topical OTC medicines (anesthetic products, anti-itch products, antibiotic creams/gels), plasters & bandages (adhesive bandages/plasters, first aid tape, gauze pads/rolled gauze, liquid bandages and other tape or bandage), first aid kits and other (anti-smoking aids, rectal medications, eye/ear drops, sleeping aids, and motion sickness). The market is valued according to retail selling price (RSP) and includes any applicable taxes. Any currency conversions used in the creation of this report have been calculated using constant 2010 annual average exchange rates.

TABLE OF CONTENTS

Introduction 8

What is this report about? 8

Who is the target reader? 8

How to use this report 8

Definitions 8

NAFTA OTC Pharmaceuticals Industry Outlook 9

OTC Pharmaceuticals in Canada 12

Market Overview 12

Market Data 13

Market Segmentation 14

Market outlook 19

Five forces analysis 20

Leading companies 26

Macroeconomic indicators 34

OTC Pharmaceuticals in Mexico 36

Market Overview 36

Market Data 37

Market Segmentation 38

Market outlook 43

Five forces analysis 44

Leading companies 50

Macroeconomic indicators 62

OTC Pharmaceuticals in The United States 64

Market Overview 64

Market Data 65

Market Segmentation 66

Market outlook 71

Five forces analysis 72

Leading companies 78

Macroeconomic indicators 88

Appendix 90

Methodology 90



LIST OF TABLES

Table 1:NAFTA countries otc pharmaceuticals industry, revenue ($m), 2006—15 9

Table 2:NAFTA countries otc pharmaceuticals industry, revenue ($m), 2006—10 10

Table 3:NAFTA countries otc pharmaceuticals industry forecast, revenue ($m), 2010—15 11

Table 4: Canada OTC pharmaceuticals market value: $ million, 2006—10 13

Table 5: Canada OTC pharmaceuticals market category segmentation: % share, by value, 2006—2010 14

Table 6: Canada OTC pharmaceuticals market category segmentation: $ million, 2006-2010 14

Table 7: Canada OTC pharmaceuticals market geography segmentation: $million, 2010 16

Table 8: Canada OTC pharmaceuticals market share: % share, by value, 2010 17

Table 9: Canada OTC pharmaceuticals market distribution: % share, by value, 2010 18

Table 10: Canada OTC pharmaceuticals market value forecast: $ million, 2010—15 19

Table 11: Johnson & Johnson: key facts 26

Table 12: Johnson & Johnson: key financials ($) 27

Table 13: Johnson & Johnson: key financial ratios 28

Table 14: GlaxoSmithKline Plc: key facts 30

Table 15: GlaxoSmithKline Plc: key financials ($) 31

Table 16: GlaxoSmithKline Plc: key financials (£) 31

Table 17: GlaxoSmithKline Plc: key financial ratios 31

Table 18: Jamieson Laboratories, Ltd.: key facts 33

Table 19: Canada size of population (million), 2006—10 34

Table 20: Canada gdp (constant 2000 prices, $ billion), 2006—10 34

Table 21: Canada gdp (current prices, $ billion), 2006—10 34

Table 22: Canada inflation, 2006—10 35

Table 23: Canada consumer price index (absolute), 2006—10 35

Table 24: Canada exchange rate, 2006—10 35

Table 25: Mexico OTC pharmaceuticals market value: $ million, 2006—10 37

Table 26: Mexico OTC pharmaceuticals market category segmentation: % share, by value, 2006—2010 38

Table 27: Mexico OTC pharmaceuticals market category segmentation: $ million, 2006-2010 38

Table 28: Mexico OTC pharmaceuticals market geography segmentation: $million, 2010 40

Table 29: Mexico OTC pharmaceuticals market share: % share, by value, 2010 41

Table 30: Mexico OTC pharmaceuticals market distribution: % share, by value, 2010 42

Table 31: Mexico OTC pharmaceuticals market value forecast: $ million, 2010—15 43

Table 32: Bayer AG: key facts 50

Table 33: Bayer AG: key financials ($) 51

Table 34: Bayer AG: key financials (€) 51

Table 35: Bayer AG: key financial ratios 52

Table 36: Johnson & Johnson: key facts 54

Table 37: Johnson & Johnson: key financials ($) 55

Table 38: Johnson & Johnson: key financial ratios 56

Table 39: Boehringer Ingelheim GmbH: key facts 58

Table 40: Boehringer Ingelheim GmbH: key financials ($) 59

Table 41: Boehringer Ingelheim GmbH: key financials (€) 59

Table 42: Boehringer Ingelheim GmbH: key financial ratios 60

Table 43: Mexico size of population (million), 2006—10 62

Table 44: Mexico gdp (constant 2000 prices, $ billion), 2006—10 62

Table 45: Mexico gdp (current prices, $ billion), 2006—10 62

Table 46: Mexico inflation, 2006—10 63

Table 47: Mexico consumer price index (absolute), 2006—10 63

Table 48: Mexico exchange rate, 2006—10 63

Table 49: United States OTC pharmaceuticals market value: $ million, 2006—10 65

Table 50: United States OTC pharmaceuticals market category segmentation: % share, by value, 2006—2010 66

Table 51: United States OTC pharmaceuticals market category segmentation: $ million, 2006-2010 66

Table 52: United States OTC pharmaceuticals market geography segmentation: $million, 2010 68

Table 53: United States OTC pharmaceuticals market share: % share, by value, 2010 69

Table 54: United States OTC pharmaceuticals market distribution: % share, by value, 2010 70

Table 55: United States OTC pharmaceuticals market value forecast: $ million, 2010—15 71

Table 56: Johnson & Johnson: key facts 78

Table 57: Johnson & Johnson: key financials ($) 79

Table 58: Johnson & Johnson: key financial ratios 80

Table 59: Pfizer Inc.: key facts 82

Table 60: Pfizer Inc.: key financials ($) 83

Table 61: Pfizer Inc.: key financial ratios 83

Table 62: Merck & Co., Inc.: key facts 85

Table 63: Merck & Co., Inc.: key financials ($) 86

Table 64: Merck & Co., Inc.: key financial ratios 86

Table 65: United States size of population (million), 2006—10 88

Table 66: United States gdp (constant 2000 prices, $ billion), 2006—10 88

Table 67: United States gdp (current prices, $ billion), 2006—10 88

Table 68: United States inflation, 2006—10 89

Table 69: United States consumer price index (absolute), 2006—10 89

Table 70: United States exchange rate, 2006—10 89



LIST OF FIGURES

Figure 1: NAFTA countries otc pharmaceuticals industry, revenue ($m), 2006—15 9

Figure 2: NAFTA countries otc pharmaceuticals industry, revenue ($m), 2006—10 10

Figure 3: NAFTA countries otc pharmaceuticals industry forecast, revenue ($m), 2010—15 11

Figure 4: Canada OTC pharmaceuticals market value: $ million, 2006—10 13

Figure 5: Canada OTC pharmaceuticals market category segmentation: $ million, 2006-2010 15

Figure 6: Canada OTC pharmaceuticals market geography segmentation: % share, by value, 2010 16

Figure 7: Canada OTC pharmaceuticals market share: % share, by value, 2010 17

Figure 8: Canada OTC pharmaceuticals market distribution: % share, by value, 2010 18

Figure 9: Canada OTC pharmaceuticals market value forecast: $ million, 2010—15 19

Figure 10: Forces driving competition in the OTC pharmaceuticals market in Canada, 2010 20

Figure 11: Drivers of buyer power in the OTC pharmaceuticals market in Canada, 2010 21

Figure 12: Drivers of supplier power in the OTC pharmaceuticals market in Canada, 2010 22

Figure 13: Factors influencing the likelihood of new entrants in the OTC pharmaceuticals market in Canada, 2010 23

Figure 14: Factors influencing the threat of substitutes in the OTC pharmaceuticals market in Canada, 2010 24

Figure 15: Drivers of degree of rivalry in the OTC pharmaceuticals market in Canada, 2010 25

Figure 16: Johnson & Johnson: revenues & profitability 28

Figure 17: Johnson & Johnson: assets & liabilities 29

Figure 18: GlaxoSmithKline Plc: revenues & profitability 32

Figure 19: GlaxoSmithKline Plc: assets & liabilities 32

Figure 20: Mexico OTC pharmaceuticals market value: $ million, 2006—10 37

Figure 21: Mexico OTC pharmaceuticals market category segmentation: $ million, 2006-2010 39

Figure 22: Mexico OTC pharmaceuticals market geography segmentation: % share, by value, 2010 40

Figure 23: Mexico OTC pharmaceuticals market share: % share, by value, 2010 41

Figure 24: Mexico OTC pharmaceuticals market distribution: % share, by value, 2010 42

Figure 25: Mexico OTC pharmaceuticals market value forecast: $ million, 2010—15 43

Figure 26: Forces driving competition in the OTC pharmaceuticals market in Mexico, 2010 44

Figure 27: Drivers of buyer power in the OTC pharmaceuticals market in Mexico, 2010 45

Figure 28: Drivers of supplier power in the OTC pharmaceuticals market in Mexico, 2010 46

Figure 29: Factors influencing the likelihood of new entrants in the OTC pharmaceuticals market in Mexico, 2010 47

Figure 30: Factors influencing the threat of substitutes in the OTC pharmaceuticals market in Mexico, 2010 48

Figure 31: Drivers of degree of rivalry in the OTC pharmaceuticals market in Mexico, 2010 49

Figure 32: Bayer AG: revenues & profitability 52

Figure 33: Bayer AG: assets & liabilities 53

Figure 34: Johnson & Johnson: revenues & profitability 56

Figure 35: Johnson & Johnson: assets & liabilities 57

Figure 36: Boehringer Ingelheim GmbH: revenues & profitability 60

Figure 37: Boehringer Ingelheim GmbH: assets & liabilities 61

Figure 38: United States OTC pharmaceuticals market value: $ million, 2006—10 65

Figure 39: United States OTC pharmaceuticals market category segmentation: $ million, 2006-2010 67

Figure 40: United States OTC pharmaceuticals market geography segmentation: % share, by value, 2010 68

Figure 41: United States OTC pharmaceuticals market share: % share, by value, 2010 69

Figure 42: United States OTC pharmaceuticals market distribution: % share, by value, 2010 70

Figure 43: United States OTC pharmaceuticals market value forecast: $ million, 2010—15 71

Figure 44: Forces driving competition in the OTC pharmaceuticals market in the United States, 2010 72

Figure 45: Drivers of buyer power in the OTC pharmaceuticals market in the United States, 2010 73

Figure 46: Drivers of supplier power in the OTC pharmaceuticals market in the United States, 2010 74

Figure 47: Factors influencing the likelihood of new entrants in the OTC pharmaceuticals market in the United States, 2010 75

Figure 48: Factors influencing the threat of substitutes in the OTC pharmaceuticals market in the United States, 2010 76

Figure 49: Drivers of degree of rivalry in the OTC pharmaceuticals market in the United States, 2010 77

Figure 50: Johnson & Johnson: revenues & profitability 80

Figure 51: Johnson & Johnson: assets & liabilities 81

Figure 52: Pfizer Inc.: revenues & profitability 83

Figure 53: Pfizer Inc.: assets & liabilities 84

Figure 54: Merck & Co., Inc.: revenues & profitability 87

Figure 55: Merck & Co., Inc.: assets & liabilities 87

• OTC Triptans in Azerbaijan
• Calming and Sleeping in Australia
• Calming and Sleeping in Croatia
• Cough, Cold and Allergy (Hay Fever) Remedies in Australia
• Cough, Cold and Allergy (Hay Fever) Remedies in Croatia
• Over-the-counter Pharmaceuticals Market in the Asia Pacific Region 2012-2016
• Over-the-counter Pharmaceuticals Market in the Asia Pacific Region 2012-2016
• Global Over-the-counter Pharmaceutical Market 2012-2016
• OTC Pharmaceuticals and Self-medication in Seven Emerging Markets
• OTC Triptans in Germany
• OTC Triptans in Sweden
• OTC Triptans in the United Kingdom
• Cough, Cold and Allergy (Hay Fever) Remedies in the US
• Rx-to-OTC Switching Strategies - New Switching Opportunities in Weight Management and Smoking Cessation, but Encouraging the Uptake of Self-Medication Remains a Challenge
• Global OTC Pharmaceuticals
• OTC Pharmaceuticals - BRIC (Brazil, Russia, India, China) Industry Guide
• OTC Pharmaceuticals - Global Group of Eight (G8) Industry Guide
• OTC Pharmaceuticals - Scandinavia Industry Guide
• OTC Pharmaceuticals - Top 5 Emerging Markets Industry Guide
• OTC Pharmaceuticals in Asia-Pacific